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Abstract
Idiotypic (Id) vaccination has shown promising results in patients with follicular lymphoma (FL). However, it still remains unclear whether
the same approach might be suitable for the treatment of other B-cell malignancies. For this reason, we recently performed an interim analysis
of patients proposed to receive this treatment at our center.
The feasibility of employing idiotype vaccines was evaluated for five different B-cell malignancies in their first relapse, both in terms of
induction and fusion, as well as overall treatment. Our data suggest that, unlike follicular lymphoma (87%), this approach is not feasible to
treat other B-cell malignancies (0–20%) such as mantle cell, small lymphocytic, diffuse large cell and Burkitt’s lymphoma (P < 0.01). The
main difficulties encountered were technical problems related to the survival of idiotype-producing hybridomas (83%) and the early loss of
idiotype production by growing hybridomas (17%).
However, it remains possible that an idiotype vaccine might still be produced through molecular means for most, if not all cases of relapsing
B-cell malignancies.
© 2004 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Currently, two ongoing phase-III clinical trials enrolling
newly diagnosed patients are evaluating the use of idiotypic
(Id) vaccination to treat follicular lymphoma (FL) [1,2].
1040-8428/$ – see front matter © 2004 Elsevier Ireland Ltd. All rights reserved.
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Through these studies, the clinical development of this treat-
ment will approach its final stages should the benefit to pa-
tients be demonstrated. However, for this critical step to be
reached, it was first necessary to demonstrate that idiotypic
determinants present in the immunoglobulin borne by FL
cells can serve both as a tumor- and patient-specific antigen
(Fig. 1; [3,4]). Subsequently, it was shown that immuniza-
tion of FL patients against such a self-antigen was possible
[5] and induced an idiotype-specific, humoral [5–8] and cel-
lular [6,7,9] immune response. Finally, it was demonstrated
that in vivo, vaccine-induced, Id-specific immune responses
can kill FL cells that have survived standard chemotherapy
(CHT; [7,8]).
However, even in the event that one or both of the ongoing
clinical trials prove successful, a number of important ques-
tions will still remain unanswered. In particular, neither trial
will determine whether Id vaccines might be applicable to
most if not all relapsed FL and/or other B-cell malignancies.
Indeed, the feasibility of using the Id vaccine ultimately de-
pends not only on the capacity to accurately reproduce the
very same immunoglobulin ex vivo, including the unique
tumor-specific Id, but also on the ability to do so both in a
safe manner and in immunotherapeutic quantities.
2. Soluble protein idiotype vaccine production
Nowadays, Id vaccines for B-cell malignancies can be
divided into two major groups: those based on the whole
immunoglobulin as a soluble protein and those based on
the DNA sequences encoding both of the immunoglobulin’s
variable regions (Fig. 1). Here, we shall center on the pro-
duction of soluble protein, since an extensive discussion of
both the methods and the potential of DNA-based Id vac-
cines falls outside the scope of this review. Nevertheless, it
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Fig. 1. Schematic representation of idiotype localization within the
monomeric immunoglobulin. Abbreviations: V: variable region; C: con-
stant region; H: heavy chain; L: light chain.
should be noted that DNA-based Id vaccines [10–14] are at
an early stage in their development as clinical tools and de-
serve to be paid plenty of attention. Indeed, should they ulti-
mately produce results comparable to those of protein-based
formulations, they might present a number of potential lo-
gistical advantages.
As far as the Id vaccines based on the whole immunoglob-
ulin as a soluble protein are concerned, there are two en-
tirely different methods to obtain them. The more estab-
lished strategy is based on the use of “rescue” fusions (i.e.:
the production of hybridomas), while the newer option is
based on recombinant technology. This disregards the op-
tion of affinity chromatography purification of a pathologi-
cally circulating paraprotein (Fig. 2), which is inapplicable
to non-Hodgkin’s lymphoma (NHL).
Again, an extensive description of the recombinant
technology used to produce the soluble protein falls out-
side the scope of this review for a number of reasons.
Firstly, because all such methods currently under inves-
tigation contain a number of steps that remain unpub-
lished due to patent-related issues. Secondly, because
our own experience with them is still relatively recent,
making it difficult to reach firm conclusions. However,
in terms of the fundamental aspects of this approach, a
relatively small number of tumor cells can be used to re-
veal the complete genetic sequence corresponding to both
variable regions of the tumor-specific, Id-containing im-
munoglobulin. Subsequently, these sequences are inserted
into especially designed vectors together with non-specific
heavy and light chain constant region sequences to ex-
press the whole recombinant immunoglobulin in vitro
[1,15].
The hybridoma-based methodology used to rescue
tumor-specific, Id-containing whole immunoglobulins
(Fig. 2) has been responsible for all the Id vaccine-related
achievements over the last fifteen years, as outlined above. A
large number of tumor cells are required for the fusion with
a purposely-selected cell line (K6H6/B5, i.e. ATCC CRL
1823) according to the published methods [16]. Among
the several hybridomas grown (Fig. 3), one is ultimately
selected according to a number of morphological, genetic,
immunological and quantitative features. In particular, the
growth of the hybridoma should be relatively fast, and as a
single colony to prevent the risk of later discovering that the
proliferating cells are not clonal (Fig. 3A). Moreover, the
hybridoma molecular fingerprint must fully overlap with
that of the corresponding tumor cell to ensure complete
identity between the tumor-specific Id and that synthesized
by the hybridoma [17]. Furthermore, the hybridoma must
indeed secrete an immunoglobulin as determined by stan-
dard ELISA. Finally, sufficient immunoglobulin must be
secreted by the hybridoma to guarantee enough material
can be obtained for all the vaccine doses as well as the
post-vaccine immunological tests.
Whichever the method used, the Id-containing im-
munoglobulin is subsequently converted into the tumor- and
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Fig. 2. Flow chart of idiotype vaccine production for B-cell malignancies. The dotted lines refer to the rescue of the idiotype-containing immunoglobulin
for B-cell malignancies with a circulating M component. The continuous lines refer to the same rescue carried out by the hybridoma technique for B-cell
malignancies with no circulating paraprotein.
Fig. 3. Schematic representation of the content of individual wells within a 96-well plate 2–3 weeks after a successful hybridoma production. (A)
Well containing a clonal, rapidly-growing hybridoma colony. (B) Well containing more than one independent colony of growing hybridomas. (C) Well
containing a clonal, slowly-growing hybridoma colony. Of course, wells featuring a combination of these characteristics are also frequently observed.
patient-specific, and therefore custom-made, vaccine
through conjugation with a carrier such as KLH and the
concomitant administration of an immunological adjuvant
such as GM-CSF [2].
3. Potential pitfalls
There are still some potential pitfalls that affect both meth-
ods currently in use to produce soluble protein Id vaccines.
While some of these pitfalls are common to both techniques,
others are particular to one or the other, either being scien-
tific or logistic in nature. However, the most important pit-
fall is still the feasibility of generating the vaccine in the
broadest sense.
In FL, it is reasonable to assume that Id vaccine generation
is feasible in about 80% of cases using hybridoma technol-
ogy and in about 95% of cases using recombinant technol-
ogy. In other NHLs, these figures remain to be determined,
although some insights into this problem will be presented
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below. The successful production of an Id vaccine may well
take up to six months when based on rescue fusions, as op-
posed to the three months required when recombinant tech-
nology is used [1]. Moreover, rescue fusions require more
tumor cells, which often translates into the need for more
invasive surgery.
On the other hand, the production of rescue fusions is now
a fairly standard and well-optimized technique. It is both
fully reproducible and reliable, in contrast to recombinant
technology that is still characterized, for better or for worse,
by a constant and secret quest for faster, easier and less
expensive means of production.
Finally, both strategies face a daily struggle to progress
within an intrinsically hostile environment (at least in terms
of funding), as custom-made therapeutic solutions are by
their very nature difficult for most traditional pharmaceuti-
cal companies to exploit. As a consequence, there are very
few centers around the world that are willing to dedicate
the necessary resources, both in terms of GMP facilities and
specialized personnel, to this particular field of clinical in-
vestigation.
4. State of the art
Until very recently, nothing was known about the feasi-
bility of using idiotypic vaccination for NHLs other than
FL. However, last year data from an interim analysis sur-
faced in the scientific literature, questioning this very pos-
sibility even before focusing on either the immunological
or clinical efficacy. First of all, our group reported the fea-
sibility of using specific idiotypic vaccination for five dif-
ferent NHL subtypes [18]. All the local IRB-approved, Id
vaccine clinical trials ongoing at our institution at that time
were evaluated based both on a single, principal endpoint,
that is the ability to administer an Id vaccine according to
an intention-to-treat. Inclusion was based on an attempt to
produce an Id vaccine only at the time of first relapse and
on the previous, formal demonstration of the presence of a
complete, clonal and tumor-specific immunoglobulin on the
tumor cell surface. The diagnosis at relapse was always con-
firmed pathologically and Id rescue was always carried out
according to the traditional hybridoma technique laid out
above [16].
The Id vaccine treatment was considered unfeasible when
the salvage therapy did not induce an adequate response to
proceed with Id vaccination (induction treatment-related),
when insufficient idiotype was generated to make the vac-
cine (fusion-related), or overall. All patients received the
CHT regime in use at our institution for their respective dis-
ease at that time of first relapse. Following their respective
protocols, patients with FL, mantle cell lymphoma (MCL)
and small lymphocytic lymphoma (SLL) received Id vac-
cination if they achieved either a complete (CR) or partial
(PR) response according to standard clinical criteria. Pa-
tients with either diffuse large cell lymphoma (DLCL) or
Burkitt’s lymphoma (BL) received Id vaccination only if
they achieved a clinical CR. Indeed, given the very differ-
ent prognostic meaning of CR and PR in either indolent
or aggressive NHL, Id vaccination was proposed as further
treatment for eligible patients with indolent lymphoma and
as active immunotherapy-based maintenance treatment for
patients with aggressive NHL. Finally, fusion-related fea-
sibility was evaluated by taking into consideration both of
the potential causes of failure: short hybridoma survival and
loss of Id production.
In total, 34 patients were enrolled in the study and all of
them were evaluated on an intention-to-treat basis. Fifteen
patients had FL, 10 had indolent lymphoma other than FL
and 9 had aggressive NHL. In terms of the feasibility of in-
duction, we found a substantial difference between indolent
(80–100%) and aggressive (40–50%) NHL subtypes. How-
ever, the data were only striking because they referred to
very different eligibility criteria for Id vaccination following
CHT. In fact, the overall response (OR) to induction treat-
ment for aggressive NHL reached 75–80% (CR + PR), but
in this group only patients achieving CR were considered
eligible to receive Id vaccination.
A far more important restriction on treatment was the
production of the Id-secreting hybridoma. Despite plating a
comparable number of 96-well plates in all cases, impor-
tant differences were found between patients with FL and
those with any other NHL studied. Specifically, while most
FL cases were characterized by a successful fusion at the
first attempt, the other NHL cases required as many as five
attempts, irrespective of the ultimate outcome of Id pro-
duction. Similarly, in most FL cases the average number
of successful fusions per 96-well plate was well above 15.
In contrast, the number for most if not all the other NHL
cases was typically less than five. All the differences be-
tween FL cases and those of all other NHL cases, in terms
of fusion-related and overall feasibility, as well as those of
both indolent and aggressive lymphoma, were statistically
significant.
It is also noteworthy that both the fusion-related and the
overall feasibility of the Id vaccine treatment for FL in first
relapse were comparable with those already described for
both newly diagnosed and relapsed patients with the same
disease [6,7]. In our series, one FL patient experienced both
pre-vaccine disease progression and failure to produce an Id
vaccine. Furthermore, no differences in induction treatment-,
fusion-related and overall Id vaccine feasibility were ob-
served among the FL cases analyzed with respect to their
histological grade [19].
Finally, the main cause for the failure to produce Id vac-
cine was the poor survival of the hybridoma (15/18 cases),
which accounted for 100% of failures in aggressive lym-
phoma (9/9 cases). Loss of Id secretion by growing hy-
bridomas accounted for only 3/18 cases of failure to pro-
duce Id vaccine. Interestingly, the Id vaccine production
success rate was substantially lower in cases of MCL, in
contrast to what was initially described with the very same
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5'-CNGAGGAGACAGGTTTATGGTGGTTTGACCTTTAGAGAGTTGCTTTACGT
GGCCTGTTTCAACACAGACCCACCCAGAGCCCTCCTGCCCTCCTTCTCCC
CCATACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCCTGGT
AACCGTCTCCTCAGG-3'
Fig. 4. Nucleotide sequence of the K6H6/B5-specific bcl-2/IgH rearrangement.
method [16] in newly diagnosed MCL patients. Indeed, re-
searchers at the NCI have recently reported that the use a
rescue fusion-related Id vaccine for MCL patients is feasi-
ble in 96% of cases [20]. Since our findings also contrast
with those relating to both newly-diagnosed and relapsed FL
cases [6,7,18], it is possible that the faster biological evolu-
tion of MCL clonal cells may reflect the presence of char-
acteristics that make first relapse MCL cases more closely
resemble first-relapse NHL other than FL in terms of the
feasibility of producing hybridoma-based Id vaccine. How-
ever, it should also be noted that the same concept does not
seem to apply to grade-III FL. In fact, at least in our hands,
while this FL subset is generally considered to being both
more aggressive and more biologically similar to DLCL, in
contrast to DLCL no problems were observed in terms of
Id vaccine production. Specifically, while the DLCL-related
hybridoma fusions failed to survive, all grade-III FL cases
(4/4) were characterized by normal hybridoma survival, al-
though in one instance failure was later provoked by the loss
of Id production.
In an attempt to explain some of the discrepancies we
found regarding the feasibility of producing Id vaccine for
the different first-relapse NHLs, we focused our attention on
the possible role of the bcl-2/IgH rearrangement within the
hybridomas used to rescue the Id-containing immunoglob-
ulin. First of all, we screened all the tumors from patients
for the expression of bcl-2 using a published nested poly-
merase chain reaction-based (PCR) protocol [21]. In the tu-
mor samples, bcl-2 was expressed in 11/15 FL, 2/5 MCL,
2/5 DLCL, 0/5 SLL and 0/5 BL cases. Subsequently, we
screened for bcl-2 expression the hybridomas from bcl-2 ex-
pressing tumors that had successfully been used to produce
the Id vaccine’s core. The results were quite straightforward
in that the success of the rescue fusion was not dependent
on the expression or activity of bcl-2. Indeed, bcl-2 positive
hybridomas were found in 7/11 FL, 1/2 MCL and 1/2 DLCL
cases, respectively.
Interestingly, all bcl-2 positive hybridomas maintained
the K6H6/B5 fusion partner-specific rearrangement in detri-
ment of that derived from the fused tumor cell (as seen by
sequencing individual bcl-2; Fig. 4). This seems to imply
that the K6H6/B5-specific bcl-2 rearrangement segregates
better than that of most NHLs when the two cell types are
fused together. However, in relation to this, another anec-
dotal finding may be of some importance. Independently
of any vaccine trial, a 33-year-old woman with bcl-2 pos-
itive FL suffered a relapse two years after the first review
and confirmed diagnosis. The relapse involved a rare form
of aggressive, highly undifferentiated but still bcl-2 posi-
tive NHL, secondary DLCL. Since we had frozen single
cell suspensions of both the diagnosis and relapse tumor,
an attempt was made to produce hybridomas from both
samples. As might have been predicted, most FL-derived,
long-term-growing and Id-secreting hybridomas were bcl-2
positive and all of these bcl-2 positive hybridomas main-
tained the K6H6/B5-derived, bcl-2/IgH rearrangement. Cu-
riously, most undifferentiated NHL-derived, Id-secreting hy-
bridomas that showed long-term growth were also bcl-2
positive. Nevertheless, all of these hybridomas retained the
tumor-derived, bcl-2/IgH rearrangement in detriment of that
derived from the K6H6/B5 fusion partner. In terms of clini-
cal outcome, the patient died four months after relapse due
to the impressively disseminated, high-dose CHT-resistant
NHL.
To complete the picture of the feasibility of producing
Id vaccines for aggressive NHL, it seems reasonable to un-
derline that investigators exploiting recombinant technology
have so far not reported problems in what is the most ad-
vanced trial in this area to date [22].
5. Conclusions
On the assumption that the ongoing, phase-III clinical
trials on idiotypic vaccination for newly-diagnosed FL
will successfully demonstrate that Id vaccines produce
clinical benefits, it is reasonable to expect an increase
in the interest in such immunotherapeutic strategies for
both newly-diagnosed and relapsed FL, as well as for
other B-cell malignancies. Our data suggest that, in the
vast majority of cases, the feasibility of idiotypic vacci-
nation for patients with first-relapse B-cell malignancies
strictly depends on the ultimate capacity to produce a vi-
able Id vaccine, rather than on the probability of inducing
a clinical response suitable for subsequent idiotypic vac-
cination. In this respect, first-relapse FL clearly appears
more suitable for hybridoma-based Id vaccine production
than any other first-relapse NHL subtype tested in our
laboratory.
As the same fusion partner (K6H6/B5) was used with all
the different malignant B-cell tumor cells [16], these results
seem to imply that B-cells other than those constituting FL
clonal populations are less prone to originate suitable hy-
bridomas with the same fusion method utilized for FL Id
vaccine production. This conclusion is further supported by
the fact that only one fusion attempt was required in most
FL cases, as opposed to the other NHL subtypes where the
pre-established, arbitrary, five-attempt cut-off, was reached
in most instances, irrespective of the ultimate Id vaccine
production outcome. Furthermore, the number of successful
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fusions with viable hybridomas was also strikingly superior
in FL cases when compared to that of any other NHL sub-
types. Similarly, the most frequent cause of failure was the
short survival of Id-secreting hybridomas, only occasionally
observed for FL hybridomas. This phenomenon might im-
ply that the most crucial step in this strategy for producing
Id vaccine is the biological stabilization of an Id-secreting
hybridoma. This is a problem that, per se, is not easily sur-
mountable when dealing with rescue fusions and might even
accelerate the transition towards recombinant technologies
[23,24]
Finally, at the time of writing it is not clear whether
the recent identification of acquired, potential glycosylation
sites within the amino acid sequences of tumor-specific im-
munoglobulins [25–27] may have an impact on either idio-
typic vaccination as a whole or the choice of the methods
by which the Id-containing immunoglobulin is rescued.
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